ValueWalk

About the Author ValueWalk

ValueWalk was started in January 2010, with a focus on value investing and value investors. As the site has grown, the scope has expanded. ValueWalk is now a news site covering all breaking financial news with an emphasis on value investing, hedge funds, large asset managers, Tech news, and general business news. The site contains archives of famous investors, and many investor resource pages. The site is famous among the value investing community as one of the best sites for evergreen and new content. ValueWalk has gained popularity among all circles for its breaking stories on hedge funds, and investigative reports on investments by major funds.

Gilead Sciences, Inc. And Visa Inc Beat Earnings Estimates

Gilead Sciences, Inc. (NASDAQ:GILD) and Visa Inc (NYSE:V) released the earnings reports from their most recently completed quarters after closing bell tonight. Gilead Sciences reported non-GAAP earnings of $2.94 per share on $7.59 billion in revenue for its first quarter. Analysts had been looking for earnings per share of $2.32 on $6.89 billion in revenue. In the same quarter a year ago, the company posted earnings of $1.48 per share on $5 billion in revenue.

Visa reported adjusted earnings of 63 cents per share on revenue of $3.4 billion, an 8% year over year increase, for its second fiscal quarter. Analysts had been looking for earnings of 62 cents per share on $3.4 billion in revenue. In the same quarter last year, the payment services processor posted earnings of 55 cents per share on $3.16 billion in revenue.

Key metrics from Gilead Sciences’ earnings report

Gilead Sciences reported net income of $2.76 per share, compared to $1.33 per share in the first quarter of last year. The drug maker’s product sales rose from $4.9 billion last year to $7.4 billion in the first quarter of this year.

Gilead Sciences also updated its guidance, raising its projections for net product sales from between $26 billion and $27 billion to between $28 billion and $29 billion for the full year.U.S. product sales rose from $3.6 billion last year to $5.2 billion this year. Europe product sales rose from $1 billion to $1.8 billion this year. The company’s antiviral product sales were $7 billion, compared to last year’s $4.5 billion. Other product sales increased from $362 million to $417 million.

Key metrics from Visa’s earnings report

Visa reported an 11% increase in payment volumes, which rose to $1.2 trillion in constant currency. The payments processor also saw an 11% increase in total transactions, which increased to $17 billion. Revenue from data processing increased 9% year over year, while international revenue increased 11%. Other revenues, including licensing fees from Visa Europe, rose 12% from last year to $204 million. Service revenues increased 8% to $1.6 billion.

“Visa reported another solid quarter of financial results against the continued backdrop of a tepid global economy,” Visa CEO Charlie Scharf said in a statement. “While the negative impacts from the strengthening of the U.S. dollar and lower gasoline prices continued to exert pressure on revenue growth, our results and volume trends have remained strong.”